Kidney involvement in COVID-19 and rationale for extracorporeal therapies
Top Cited Papers
- 9 April 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Nephrology
- Vol. 16 (6), 308-310
- https://doi.org/10.1038/s41581-020-0284-7
Abstract
The prevalence of direct kidney involvement in novel coronavirus disease (COVID-19) is low, but such involvement is a marker of multiple organ dysfunction and severe disease. Here, we explore potential pathways of kidney damage and discuss the rationale for extracorporeal support with various blood purification strategies in patients who are critically ill with COVID-19.Keywords
This publication has 11 references indexed in Scilit:
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Clinical Characteristics of Covid-19 in ChinaThe New England Journal of Medicine, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaThe New England Journal of Medicine, 2020
- Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellumBlood Purification, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Blood Purification Techniques for Sepsis and Septic AKISeminars in Nephrology, 2019
- Factors associated with acute kidney injury in acute respiratory distress syndromeAnnals of Intensive Care, 2019
- Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trialIntensive Care Medicine, 2018
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017
- Lung–Kidney Cross-Talk in the Critically Ill PatientAmerican Journal of Respiratory and Critical Care Medicine, 2016